Organization (Industry)
DSM-Firmenich AG
ClinicalTrials.gov lists DSM-Firmenich AG as lead sponsor of 44 trials, counting the companies grouped under it. DSM-Firmenich AG itself has 8 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. Companies grouped under this one are not included. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 4 registered with a 2026 start date. The dashed outline is the pace from the 4 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 4.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Logo DSM-Firmenich AG, via Wikimedia Commons, Public domain. Shown to identify the organization; it may be a registered trademark.
This page covers DSM-Firmenich AG and 2 companies grouped under it: 44 lead-sponsored trials (0 its own, 44 in the grouped companies) and 5 legal-entity registrations (2 its own, 3 in the grouped companies).
Companies grouped under this page (2)
Shown in this order: most lead trials first.
| Company | Lead trials | Legal entities |
|---|---|---|
| dsm-firmenich Switzerland AG | 44 | 1 |
| DSM Nutritional Products AG | 0 | 2 |
Disease areas (65)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Diabetes Mellitus | 9 |
| Insulin Resistance | 7 |
| Diabetes Mellitus, Type 2 | 6 |
| Malnutrition | 6 |
| Obesity | 6 |
Showing 5 of 65 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 4 |
| 2025 | 7 |
| 2024 | 3 |
| 2023 | 1 |
| 2022 | 7 |
| 2021 | 1 |
| 2020 | 4 |
| 2019 | 3 |
| 2018 | 5 |
| 2017 | 3 |
Showing 10 of 24 years.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Approved assets (8)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Calcium-vitamin D3 | 2 |
| Calcifediol | 1 |
| Vitamin C | 2 |
| Vitamin A | 1 |
| Riboflavin | 1 |
Showing 5 of 8 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 53% hit target (n=17) | 50% on time (n=18) |
Journals published in (113)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The American journal of clinical nutrition | 18 |
| The Journal of nutrition | 16 |
| Investigative ophthalmology & visual science | 5 |
| JAMA | 4 |
| PloS one | 4 |
Showing 5 of 113 journals.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 1 |
Manufacturing and distribution sites (5)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| DSM Nutritional Products (UK) Ltd | DALRY, GB | FDA, Health Canada | DSM Nutritional Products (UK) Limited |
| DSM Nutritional Products Inc (Mexico) | Guadalajara, MX | Health Canada | DSM Nutritional Products Inc (Mexico) |
| DSM Nutritional Products GmbH | Grenzach-Wyhlen, DE | EMA, FDA, Health Canada | DSM Nutritional Products GmbH |
| DSM Nutritional Products, Inc. | Belvidere, US | Health Canada | DSM Nutritional Products, Inc. |
| DSM Nutritional Products (UK) Limited | HEANOR, GB | EMA | DSM Nutritional Products (UK) Limited |
Organization relationships (25)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Government of the United States of America | Co sponsors trial with | 3 |
| Maastricht University Medical Center | Co sponsors trial with | 2 |
| University of Manitoba | Co sponsors trial with | 1 |
| Mayo Clinic | Co sponsors trial with | 1 |
| Forest Laboratories (United States) | Co sponsors trial with | 1 |
Showing 5 of 25 relationships.
Latest dated events (109)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-20 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-07-13 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-01-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-10-27 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 109 events.
Biomarker capability evidence (112)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ABCC6 | Trial collaborator | Named in trial inclusion criteria |
| ALK | Trial collaborator | Named in trial inclusion criteria |
| BCAR1 | Trial collaborator | Primary endpoint in a Phase 3 trial |
| BCHE | Trial collaborator | Named in trial inclusion criteria |
| CSE1L | Trial collaborator | Primary endpoint in a Phase 3 trial |
Showing 5 of 112 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, fda recalls, fda import refusals, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.